Company Overview

Perspective Therapeutics, Inc. is a clinical-stage biotechnology company operating in the radiopharmaceutical and oncology industries. The company focuses on the development of targeted alpha-particle therapies and diagnostic imaging agents designed to treat and detect cancer at the cellular level. Its core strategy centers on leveraging proprietary alpha-emitting isotopes combined with tumor-targeting molecules to deliver potent radiation directly to cancer cells while limiting damage to surrounding healthy tissue.

The company’s primary business is research and development, with no approved commercial products to date. Its revenue is not driven by product sales but rather by capital raises, strategic collaborations, and grants. Perspective Therapeutics traces its roots to the early development of radiopharmaceutical platforms and evolved through mergers and restructurings, culminating in its current form and public listing on Nasdaq under the ticker CATX, where it continues to advance a focused pipeline in targeted alpha therapy.

Business Operations

Perspective Therapeutics operates through a single integrated business model encompassing discovery, preclinical development, clinical trials, and isotope production. Its core operations are organized around Targeted Alpha Therapy (TAT) Programs, which combine proprietary targeting ligands with alpha-emitting isotopes such as actinium-225. The company also develops diagnostic imaging agents that support patient selection and therapy monitoring.

Operations are primarily based in the United States, with internal capabilities in radiochemistry, isotope handling, and early-stage manufacturing. The company controls specialized laboratory infrastructure for handling radioactive materials and relies on a mix of internal development and external contract research organizations for clinical execution. It maintains relationships with academic institutions and nuclear isotope suppliers to support its research and clinical supply chain.

Strategic Position & Investments

The company’s strategic direction is centered on establishing a vertically integrated radiopharmaceutical platform, spanning isotope production, drug development, and clinical translation. Growth initiatives focus on advancing multiple oncology programs into and through early- and mid-stage clinical trials, particularly in solid tumors with high unmet medical need. Perspective Therapeutics has made targeted investments in isotope production capabilities to secure long-term access to critical alpha-emitting materials.

Rather than pursuing large-scale acquisitions, the company has emphasized internal pipeline expansion and selective in-licensing of complementary technologies. Its portfolio includes multiple wholly owned development candidates and platform technologies designed to be adaptable across tumor types. Emerging areas of focus include next-generation targeting ligands and scalable isotope manufacturing processes, which are intended to strengthen its competitive position in the evolving radiopharmaceutical sector.

Geographic Footprint

Perspective Therapeutics is headquartered in the United States, with its principal executive offices and laboratory operations located in North America. Its activities are primarily concentrated domestically, reflecting its current clinical-stage focus and U.S.-based regulatory strategy. The company conducts clinical trials at multiple investigational sites, primarily within the United States.

While it does not maintain significant standalone international operations, the company’s strategic reach extends globally through collaborations, isotope supply relationships, and participation in international scientific and medical research networks. Its technologies and development programs are intended for global oncology markets, subject to future regulatory approvals.

Leadership & Governance

Perspective Therapeutics is led by an executive team with experience in biotechnology, oncology drug development, and radiopharmaceutical sciences. The leadership emphasizes scientific rigor, disciplined capital allocation, and the development of differentiated cancer therapies using targeted radiation technologies. Corporate governance follows standard U.S. public company practices, with oversight by a board of directors that includes industry and financial expertise.

Key executives include:

• William S. Williams – Chief Executive Officer
• Chris Lowe – Chief Financial Officer
• Dr. Amy C. Brake – Chief Medical Officer
• Dr. Olivier Rixe – Chief Scientific Officer
• Jeff Burton – Chief Operating Officer